The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in Nonalcoholic Steatohepatitis (NASH) Treatment (FLINT) Trial

Trial Profile

The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in Nonalcoholic Steatohepatitis (NASH) Treatment (FLINT) Trial

Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 Jun 2017

At a glance

  • Drugs Obeticholic acid (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Therapeutic Use
  • Acronyms FLINT
  • Most Recent Events

    • 12 Jun 2017 Data from the retrospective analysis of this trial published in an Intercept Pharmaceuticals Media Release.
    • 12 Jun 2017 According to an Intercept Pharmaceuticals media release, data from the retrospective analysis of this trial were presented at the American Diabetes Association's 77th Scientific Sessions.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top